Prema Maria Mertz

Array ( [id] => 18939670 [patent_doc_number] => 20240034809 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-01 [patent_title] => HETERODIMERIC IGA FC CONSTRUCTS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/265341 [patent_app_country] => US [patent_app_date] => 2021-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35665 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 170 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18265341 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19050882 [patent_doc_number] => 20240092851 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => IL-7 FUSION PROTEIN AND RELATED METHODS [patent_app_type] => utility [patent_app_number] => 18/254223 [patent_app_country] => US [patent_app_date] => 2021-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10564 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18254223 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18861886 [patent_doc_number] => 20230416321 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => TGF-Beta Polypeptides [patent_app_type] => utility [patent_app_number] => 18/038402 [patent_app_country] => US [patent_app_date] => 2021-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 84976 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18038402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17443771 [patent_doc_number] => 20220064276 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/530786 [patent_app_country] => US [patent_app_date] => 2021-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 115355 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17530786 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19210740 [patent_doc_number] => 11999788 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-04 [patent_title] => Treatment or prevention method of radiation damage by administration of IL-5 receptor alpha chain binding antibody [patent_app_type] => utility [patent_app_number] => 17/530150 [patent_app_country] => US [patent_app_date] => 2021-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 24 [patent_no_of_words] => 18841 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 224 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17530150 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17868483 [patent_doc_number] => 20220291219 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => SYSTEMS AND COMPOSITIONS FOR DIAGNOSING BARRETT'S ESOPHAGUS AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/529598 [patent_app_country] => US [patent_app_date] => 2021-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31492 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17529598 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20578486 [patent_doc_number] => 12570728 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-10 [patent_title] => Combinations of antibodies and bispecific antibodies comprising antigen-binding specifically recognizing [patent_app_type] => utility [patent_app_number] => 18/036949 [patent_app_country] => US [patent_app_date] => 2021-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 37 [patent_no_of_words] => 68107 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18036949 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879129 [patent_doc_number] => 20240002498 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => HEAVY CHAIN ANTIBODIES BINDING TO FOLATE RECEPTOR ALPHA [patent_app_type] => utility [patent_app_number] => 18/253197 [patent_app_country] => US [patent_app_date] => 2021-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24013 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18253197 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879151 [patent_doc_number] => 20240002520 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => TREATMENT OF CASTLEMAN DISEASE [patent_app_type] => utility [patent_app_number] => 18/253017 [patent_app_country] => US [patent_app_date] => 2021-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12171 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18253017 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19242030 [patent_doc_number] => 12012449 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-18 [patent_title] => Human IL-23 antigen binding proteins [patent_app_type] => utility [patent_app_number] => 17/525421 [patent_app_country] => US [patent_app_date] => 2021-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 30372 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17525421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20206355 [patent_doc_number] => 20250276075 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-04 [patent_title] => METHODS OF TREATING AXL-EXPRESSING CANCERS WITH ANTI-AXL ANTIBODIES, ANTIBODY FRAGMENTS AND THEIR IMMUNOCONJUGATES [patent_app_type] => utility [patent_app_number] => 18/252542 [patent_app_country] => US [patent_app_date] => 2021-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55408 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18252542 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18085540 [patent_doc_number] => 11535658 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-27 [patent_title] => Activatable interleukin-2 polypeptides and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/523432 [patent_app_country] => US [patent_app_date] => 2021-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 98 [patent_no_of_words] => 34007 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17523432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17426926 [patent_doc_number] => 20220054634 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => Anti-IL-23 Antibodies, Compositions, Methods and Uses [patent_app_type] => utility [patent_app_number] => 17/522423 [patent_app_country] => US [patent_app_date] => 2021-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30694 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 174 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17522423 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18830862 [patent_doc_number] => 20230399387 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => ANTIBODIES FOR USE IN THE DETECTION AND TREATMENT OF HEART DISEASE [patent_app_type] => utility [patent_app_number] => 18/033464 [patent_app_country] => US [patent_app_date] => 2021-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39245 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18033464 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879144 [patent_doc_number] => 20240002513 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => DOSING AND ADMINISTRATION OF NON-FUCOSYLATED ANTI-CTLA-4 ANTIBODY AS MONOTHERAPY [patent_app_type] => utility [patent_app_number] => 18/251935 [patent_app_country] => US [patent_app_date] => 2021-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10152 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18251935 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19065723 [patent_doc_number] => 20240100149 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => SARS-COV-2 CONSTRUCTS, VACCINES, AND METHODS [patent_app_type] => utility [patent_app_number] => 18/251963 [patent_app_country] => US [patent_app_date] => 2021-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14340 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18251963 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17687740 [patent_doc_number] => 20220195032 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/519069 [patent_app_country] => US [patent_app_date] => 2021-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33521 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17519069 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19300087 [patent_doc_number] => 20240228656 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-11 [patent_title] => EPCAM TARGETING TRISPECIFIC PROTEIN FOR TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 18/252007 [patent_app_country] => US [patent_app_date] => 2021-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50943 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18252007 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19373939 [patent_doc_number] => 12065488 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-20 [patent_title] => Anti-IL-6 antibody [patent_app_type] => utility [patent_app_number] => 17/516082 [patent_app_country] => US [patent_app_date] => 2021-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 26 [patent_no_of_words] => 41091 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 294 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17516082 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18830873 [patent_doc_number] => 20230399398 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => CD7-TARGETING HUMANIZED ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/034170 [patent_app_country] => US [patent_app_date] => 2021-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9897 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18034170 [rel_patent_id] =>[rel_patent_doc_number] =>)